Diffuse Large B-Cell Lymphoma Unclassifiable

hematologic malignancy

Identifier: CI-CAN-00005111
Entity page: /cancer/diffuse-large-b-cell-lymphoma-unclassifiable ↗
Edges: 80

Neighbours: 15 genes19 drugs10 trials
Drawn: 44 of 44 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Diffuse Large B-Cell Lymphoma Unclassifiable altered in cohorts of …ALTERED_INderived15 of 44show all (up to 200)
← altered in cohorts of	KMT2D 247 / 1,001 cases (25 %) · ssm · dlbcl_duke_2017 · largest of 2 cohorts	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	2	Observed	cbioportal	graph →
← altered in cohorts of

Diffuse Large B-Cell Lymphoma Unclassifiable investigated in trials for …INVESTIGATED_IN_TRIALSderived19 of 19show fewer
→ investigated in trials for	Rituximabmonoclonal antibody 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 6 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Azacitidinesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Belinostatsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Copanlisibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ifosfamidesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Polatuzumab Vedotinadc 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Selinexorsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Tazemetostatsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →

Diffuse Large B-Cell Lymphoma Unclassifiable investigated in trials for …INVESTIGATED_IN_TRIALSderived19 of 19show fewer

→ investigated in trials for

Rituximabmonoclonal antibody

8 trials (3 active) · roll-up of the cancer and its descendants

—

Diffuse Large B-Cell Lymphoma Unclassifiable

Observed

Diffuse Large B-Cell Lymphoma Unclassifiable studied in …STUDIED_INderived10 of 17show all (up to 200)
→ studied in	NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ studied in	NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ALIAS · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ studied in	NCT03656835NA · active not recruiting Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT05755087Phase 1 · recruiting Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT04512716early Phase 1 · recruiting Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Unclassifiable	1	Observed	clinicaltrials	graph →
→ studied in	NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ALIAS · 17 trials mapped (11 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains